Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort
Wafa Ali Aldhaleei, Tadesse Melaku Abegaz, Akshaya Srikanth Bhagavathula
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 199-199
Open Access | Times Cited: 22

Showing 22 citing articles:

How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
Ralf Weiskirchen, Amedeo Lonardo
British Journal of Pharmacology (2025)
Open Access | Times Cited: 3
Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
Xu He, Wei Zhao, Ping Li, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access | Times Cited: 1
The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review
Silvia Tempia Valenta, Alba Nicastri, Federica Perazza, et al.
Current Treatment Options in Psychiatry (2024)
Closed Access | Times Cited: 6
Perioperative Management of Patients Taking Glucagon-like Peptide-1 Receptor Agonists: Applying Evidence to Clinical Practice
Adriana D. Oprea, Guillermo E. Umpierrez, BobbieJean Sweitzer, et al.
Anesthesiology (2024) Vol. 141, Iss. 6, pp. 1141-1161
Closed Access | Times Cited: 6
Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future
Ying Jie Chee, Rinkoo Dalan
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1386-1386
Open Access | Times Cited: 4
An update on drug repurposing in Parkinson’s disease: Preclinical and clinical considerations
Michela Salvadè, Mónica Di Luca, Fabrizio Gardoni
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117862-117862
Closed Access
Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy – a retrospective cohort study
Chino Aneke-Nash, Kay S. Hung, Elizabeth Wall‐Wieler, et al.
BMJ Open Gastroenterology (2025) Vol. 12, Iss. 1, pp. e001704-e001704
Open Access
Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review
Abdullah Al Lawati, Ayman Alhabsi, R. Rahul, et al.
Diseases (2025) Vol. 13, Iss. 5, pp. 129-129
Open Access
Diabetes and susceptibility to COVID-19: Risk factors and preventive and therapeutic strategies
Jingwen Liu, Xiao Jun Huang, Mingke Wang, et al.
World Journal of Diabetes (2024) Vol. 15, Iss. 8, pp. 1663-1671
Open Access | Times Cited: 3
Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface
Jacques Raubenheimer, Pieter Hermanus Myburgh, Akshaya Srikanth Bhagavathula
BMC Global and Public Health (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 3
Oral TIX100 protects against obesity‐associated glucose intolerance and diet‐induced adiposity
SeongHo Jo, Jing Gu, Junqin Chen, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Evidence of phenolic compounds as modulators of ChREBP and NRF2 in type 2 diabetes: a review of their potential for drug development
Carina Proença, M. Graça Lobo, Ana T. Rufino, et al.
Phytochemistry Reviews (2025)
Closed Access
Myths and Facts Regarding Low-Carbohydrate Diets
Nina Teicholz, Steven M. Croft, Ignacio Cuaranta, et al.
Nutrients (2025) Vol. 17, Iss. 6, pp. 1047-1047
Open Access
Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis
Moaz Safwan, Mariam Safwan Bourgleh, Shahad Alotaibi, et al.
Annals of Saudi Medicine (2025) Vol. 45, Iss. 2, pp. 129-143
Open Access
Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system
Kenneth L. McCall, Keri A. Mastro Dwyer, Rowan G. Casey, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP/PS1 mouse model of Alzheimer’s disease
Noor Abdulhameed, Alice Babin, Kim M. Hansen, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Cardiometabolic Crossroads: Obesity, Sleep-Disordered Breathing, and Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction – A Mini-Review
Fulvio Cacciapuoti, Ciro Mauro, Valentina Capone, et al.
Heart and Mind (2024)
Open Access | Times Cited: 1
Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database
Samuel Prince Osei, Edwin Akomaning, Teodora Francesca Florut, et al.
Diagnostics (2024) Vol. 14, Iss. 24, pp. 2829-2829
Open Access | Times Cited: 1
Sweetening the deal: An infodemiological study of worldwide interest in semaglutide using Google Trends
Jacques Raubenheimer, Pieter Hermanus Myburgh, Akshaya Srikanth BHAGAVATH
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients
Vincenzo Quagliariello, Maria Laura Canale, Irma Bisceglia, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 20, pp. 11299-11299
Open Access | Times Cited: 1
Beyond glycaemic control: reduced pneumonia and sepsis risk with GLP-1 RAs and SGLT2 inhibitors in patients with type 2 diabetes
Ramin Rezaeianzadeh, Mohsen Sadatsafavi
Thorax (2024), pp. thorax-222540
Closed Access | Times Cited: 1
The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology
Sofía Echeverry-Guerrero, Salomé González-Vélez, Ana-Sofía Arévalo-Lara, et al.
Pharmacoepidemiology (2024) Vol. 3, Iss. 4, pp. 365-372
Open Access
Page 1

Scroll to top